Patient-Reported Outcomes in ATLAS and FLAIR Participants on Long-Acting Regimens of Cabotegravir and Rilpivirine Over 48 Weeks

The phase 3 ATLAS and FLAIR studies demonstrated that maintenance with Long-Acting (LA) intramuscular cabotegravir and rilpivirine is non-inferior in efficacy to current antiretroviral (CAR) oral therapy. Both studies utilized Patient-Reported Outcome instruments to measure treatment satisfaction (H...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:AIDS Behav
Main Authors: Murray, Miranda, Antela, Antonio, Mills, Anthony, Huang, Jenny, Jäger, Hans, Bernal, Enrique, Lombaard, Johan, Katner, Harold, Walmsley, Sharon, Khuong-Josses, Marie-Aude, Hudson, Krischan, Dorey, David, Griffith, Sandy, Spreen, William, Vanveggel, Simon, Shaefer, Mark, Margolis, David, Chounta, Vasiliki
Formato: Artigo
Idioma:Inglês
Publicado em: Springer US 2020
Assuntos:
Original Paper
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7667137/
https://ncbi.nlm.nih.gov/pubmed/32447500
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10461-020-02929-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados